New York State Common Retirement Fund Has $758,000 Position in Paratek Pharmaceuticals Inc (NASDAQ:PRTK)

New York State Common Retirement Fund lessened its holdings in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 23.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,183 shares of the specialty pharmaceutical company’s stock after selling 9,216 shares during the period. New York State Common Retirement Fund owned 0.11% of Paratek Pharmaceuticals worth $758,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in PRTK. C WorldWide Group Holding A S lifted its stake in Paratek Pharmaceuticals by 46.8% during the 3rd quarter. C WorldWide Group Holding A S now owns 645,100 shares of the specialty pharmaceutical company’s stock valued at $16,192,000 after acquiring an additional 205,700 shares during the period. Russell Investments Group Ltd. increased its position in shares of Paratek Pharmaceuticals by 481.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 63,787 shares of the specialty pharmaceutical company’s stock valued at $1,538,000 after purchasing an additional 52,818 shares during the last quarter. State Street Corp increased its position in shares of Paratek Pharmaceuticals by 112.3% during the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock valued at $14,850,000 after purchasing an additional 325,856 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Paratek Pharmaceuticals by 71.3% during the 2nd quarter. Alliancebernstein L.P. now owns 20,900 shares of the specialty pharmaceutical company’s stock valued at $504,000 after purchasing an additional 8,700 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Paratek Pharmaceuticals by 40.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 131,723 shares of the specialty pharmaceutical company’s stock valued at $3,175,000 after purchasing an additional 38,222 shares during the last quarter. Hedge funds and other institutional investors own 84.30% of the company’s stock.

Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) opened at $15.93 on Friday. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49. The stock has a market cap of $442.86, a P/E ratio of -4.27 and a beta of 0.69. Paratek Pharmaceuticals Inc has a fifty-two week low of $13.95 and a fifty-two week high of $29.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative return on equity of 100.84% and a negative net margin of 1,236.38%. equities research analysts anticipate that Paratek Pharmaceuticals Inc will post -3.32 earnings per share for the current year.

Several equities research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Robert W. Baird reissued a “buy” rating and issued a $40.00 target price on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 17th. Guggenheim began coverage on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 target price for the company. Finally, ValuEngine lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $40.00.

WARNING: “New York State Common Retirement Fund Has $758,000 Position in Paratek Pharmaceuticals Inc (NASDAQ:PRTK)” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2018/01/21/new-york-state-common-retirement-fund-has-758000-holdings-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply